SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Morria Biopharmaceuticals Plc Announces Positive Safety, Tolerability and Preliminary Efficacy Results for MRX-4 Phase II Study in Allergic Rhinitis at the EAACI Congress